Wall Street is uber-bullish on these two Ark Invest holdings.
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders.
908 Devices Inc. (MASS) delivered earnings and revenue surprises of -11.43% and 9.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) delivered earnings and revenue surprises of 21.43% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc ., (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced the release of a data analysis tool that provides a quick and...
908 Devices Inc ., (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced that National Resilience, Inc. (Resilience), a technology-focused...
908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2023 before market...
908 Devices Inc. (MASS) delivered earnings and revenue surprises of -40.91% and 1.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December...
Masimo (MASI) delivered earnings and revenue surprises of 12.82% and 2.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?